Black adults with a certain genetic mutation have much lower bad cholesterol and are way less likely to get heart disease over 15 years — this shows that keeping cholesterol low from an early age could really protect your heart, even if you're at higher risk.
See the scientific wording
In Black adults, the presence of a nonsense mutation in the PCSK9 gene is associated with a 28 percent reduction in mean LDL cholesterol levels and an 88 percent lower incidence of coronary heart disease over a 15-year period, with a hazard ratio of 0.11, indicating that genetically driven lifelong lowering of LDL cholesterol is strongly correlated with reduced cardiovascular risk, even in high-risk populations.
Correlational — new studies may shift this
ObservationalOne moderate-quality study links this claim to the outcome, but causation is not established.
What the research says
1 study reviewedSupporting (1)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
Cohort StudyHuman2006
The study found that Black adults with a specific genetic change in the PCSK9 gene had much lower bad cholesterol and far fewer heart problems over 15 years, just like the claim says.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Black adults with a certain genetic mutation have much lower bad cholesterol and are way less likely to get heart disease over 15 years — this shows that keeping cholesterol low from an early age could really protect your heart, even if you're at higher risk.
Evidence from Studies
Supporting (1)
Community contributions welcome
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
The study found that Black adults with a specific genetic change in the PCSK9 gene had much lower bad cholesterol and far fewer heart problems over 15 years, just like the claim says.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of PCSK9 Loss-of-Function Mutations and Cardiovascular Outcomes in Black Populations
A systematic review and meta-analysis of prospective cohort studies examining PCSK9 nonsense mutations in Black adults, pooling data on LDL cholesterol changes and coronary heart disease incidence over at least 10 years of follow-up.
Randomized Trial of PCSK9 Inhibitor vs Placebo in Black Adults with Elevated Cardiovascular Risk
Double-blind, placebo-controlled RCT in Black adults with elevated baseline cardiovascular risk, randomizing participants to PCSK9 inhibitor therapy vs placebo, measuring LDL changes and incident coronary heart disease over 15 years.
Longitudinal Cohort Study of PCSK9 Mutation Carriers in the Black Adult Population
Prospective cohort study following genetically screened Black adults (carriers vs non-carriers of PCSK9 nonsense mutations) for 15 years, measuring annual LDL levels and recording incident coronary heart disease events.
Case-Control Study of PCSK9 Mutations in Black Adults with and without Coronary Heart Disease
Matched case-control study of Black adults with confirmed coronary heart disease (cases) versus healthy controls, genotyped for PCSK9 nonsense mutations, with adjustment for LDL levels and other risk factors.
Cross-Sectional Analysis of PCSK9 Mutation Status and LDL Cholesterol in Black Adults
Cross-sectional study measuring PCSK9 genotype and serum LDL cholesterol in a representative sample of Black adults, analyzing mean differences by mutation status.